Biofrontera Ownership
| BFRI Stock | USD 0.78 0.01 1.27% |
Biofrontera | Build AI portfolio with Biofrontera Stock |
Biofrontera Stock Ownership Analysis
About 12.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.65. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biofrontera recorded a loss per share of 1.5. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 5th of July 2023. Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. Biofrontera operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 69 people. For more info on Biofrontera please contact Erica CPA at 781 245 1325 or go to https://www.biofrontera-us.com.Biofrontera Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Biofrontera is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biofrontera backward and forwards among themselves. Biofrontera's institutional investor refers to the entity that pools money to purchase Biofrontera's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tower Research Capital Llc | 2025-03-31 | 0.0 | Citadel Advisors Llc | 2025-06-30 | 0.0 | Millennium Management Llc | 2025-03-31 | 0.0 | Scotia Capital Inc | 2025-03-31 | 0.0 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 0.0 | Jpmorgan Chase & Co | 2025-06-30 | 0.0 | Advisor Group Holdings, Inc. | 2025-03-31 | 0.0 | Two Sigma Securities, Llc | 2025-06-30 | 0.0 | Rosalind Advisors, Inc. | 2025-06-30 | 976.4 K | Aigh Capital Management, Llc | 2025-06-30 | 974.5 K | Geode Capital Management, Llc | 2025-06-30 | 40.4 K |
Biofrontera Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biofrontera insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biofrontera's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biofrontera insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vv Beteiligungen Aktiengesellschaft over two months ago Insider Trading | ||
Link Christian Alexander Ansgar over three months ago Insider Trading | ||
Leffler Eugene Frederick over three months ago Disposition of 87500 shares by Leffler Eugene Frederick of Biofrontera subject to Rule 16b-3 | ||
Hermann Luebbert over six months ago Acquisition by Hermann Luebbert of 113379 shares of Biofrontera at 4.77 subject to Rule 16b-3 | ||
Borer John J Iii over a year ago Acquisition by Borer John J Iii of 22000 shares of Biofrontera subject to Rule 16b-3 | ||
Hermann Luebbert over a year ago Acquisition by Hermann Luebbert of 190840 shares of Biofrontera subject to Rule 16b-3 | ||
Hermann Luebbert over a year ago Disposition of 4771 shares by Hermann Luebbert of Biofrontera subject to Rule 16b-3 | ||
Wedge Loretta M. over a year ago Insider Trading | ||
Luebbert Hermann over a year ago Exercise or conversion by Luebbert Hermann of 95420 shares of Biofrontera subject to Rule 16b-3 |
Biofrontera Outstanding Bonds
Biofrontera issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Biofrontera uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Biofrontera bonds can be classified according to their maturity, which is the date when Biofrontera has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biofrontera. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is there potential for Biotechnology market expansion? Will Biofrontera introduce new products? Factors like these will boost the valuation of Biofrontera. Projected growth potential of Biofrontera fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.50) | Revenue Per Share | Quarterly Revenue Growth (0.23) | Return On Assets | Return On Equity |
Understanding Biofrontera requires distinguishing between market price and book value, where the latter reflects Biofrontera's accounting equity. The concept of intrinsic value - what Biofrontera's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Biofrontera's price substantially above or below its fundamental value.
It's important to distinguish between Biofrontera's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biofrontera should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biofrontera's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.